CD274 and renal cell carcinoma: Subgroup analysis also identified that PD-L1 positive melanoma (RR = 1.42, 95% CI: 1.22–1.65, P < 0.001), NSCLC (RR = 2.61, 95% CI: 1.87–3.65, P < 0.001) and RCC patients (RR = 1.91, 95% CI: 1.06–3.44, P = 0.032) had a significant increase in the response rates (Table 3 and Supplementary Figure S3C).